Developed jointly by AstraZeneca and Amgen, tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP) activity. The companies updated their partnership agreement in ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen said its experimental weight loss injection ... the existing drugs on the market because it is a so-called peptide antibody conjugate, which refers to a monoclonal antibody linked to two ...

On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”).

Amgen said it has started two critical late ... with the existing drugs on the market because it is a so-called peptide antibody conjugate, which refers to a monoclonal antibody linked to two ...

In addition, Amgen has turned its expertise in antibody manufacturing into a leading position in the development of biosimilars of competitor drugs. Most recently, Amgen shares advanced in 2Q ...